Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Language
Year range
1.
Chinese Journal of Primary Medicine and Pharmacy ; (12): 2591-2594, 2015.
Article in Chinese | WPRIM | ID: wpr-481719

ABSTRACT

Objective To evaluate the clinical prevention and cure efficiency of panax notoginosides(PNS) in patients with chronic renal failure.Methods 60 patients with chronic renal failure were selected and randomly divided into the control group and the observation group,with 30 cases in each group by random number table.The patients in the control group underwent regular maintenance hemodialysis(MHD),while the patients in the observa-tion group were given PNS glucose injection on the base of the control group for two months treatment.Comparison was made between the two groups in the aspect of liver filament four items,renal function,blood lipids and the levels of TGF-β1 ,TIMP-1 expression for renal fibrosis.Results After two months treatment,the liver filament four items (t=3.94-5.62,all P<0.05),renal function (t=4.15,4.29,all P<0.05),blood lipids (t=3.83 -5.47,all P<0.05)and the level of TGF-β1,TIMP-1 were all significantly decreased in the observation group,while HA, blood lipids and the level of TGF-β1(t=5.19,P<0.01),TIMP-1(t=4.16,P<0.05)were also decreased in the control group.All the indexes of the observation group were much significant than those of the control group.Total effective rate of the observation group was 83.33%,which was significantly higher than 66.67% of the control group (χ2 =5.16,P<0.05).There was no adverse reaction in the observation group.Conclusion PNS could improve renal fibrosis by lowering the level of TGF-β1 and TIMP-1 ,and could be used as conventional auxiliary drug for patients with chronic renal failure.

2.
Chinese Journal of Postgraduates of Medicine ; (36): 28-30, 2011.
Article in Chinese | WPRIM | ID: wpr-384298

ABSTRACT

Objective To explore the effects oflosartan on brain natriuretic peptide(BNP)and C-reactive protein(CLRP)in diabetic cardiomyopathy patients. Methods Sixty diabetics were divided into diabetic control group(30 cases)and diabetic cardiomyopathy group(30 cases), and the levels of BNP and CRP in plasma were determined. Then, diabetic cardiomyopathy group were divided into conventional treatment group(15 cases)and losartan treatment group(15 cases)by random digits table to take corresponding treatment for 12 weeks. The changes of cardiac function, the levels of BNP and CRP in plasma were detected and compared. Results The levels of BNP and CRP in diabetic cardiomyopathy group [(331.27 ±65.64)ng/L,(26.10±10.13)mg/L]were significantly higher than those in diabetic control group[(76.09±39.14)ng/L,(7.03±2.71)mg/L](P<0.01). After treatment 12 weeks, the levels of BNP and CRP were significantly lower, left ventricular ejection fraction was significantly higher and left ventricular end-diastolic diameter was significantly lower in losartan treatment group than those in conventional treatment group(P<0.05).Conclusions The increasing levels of BNP and CRP can reflect clinical severity of diabetic cardiomyopathy.Losartan can decrease the levels of BNP and CRP, and improve heart function, and it has better effective on diabetic cardiomyopathy.

SELECTION OF CITATIONS
SEARCH DETAIL